NCT01119625View on ClinicalTrials.gov

Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose

PHASE3CompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

July 12, 2010

Primary Completion Date

February 17, 2011

Study Completion Date

February 17, 2011

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

Pneumococcal vaccine GSK1024850A

Intramuscular injection, one dose

BIOLOGICAL

Infanrix-IPV/Hib

Intramuscular injection, one dose

Trial Locations (3)

119074

GSK Investigational Site, Singapore

229899

GSK Investigational Site, Singapore

688846

GSK Investigational Site, Singapore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01119625 - Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose | Biotech Hunter | Biotech Hunter